ライフサイエンスコーパス: cardiovascular risk

1 s with CKD on hemodialysis exhibit increased cardiovascular risk.

2 >/=24 hours and were considered at increased cardiovascular risk.

3 ed play a role in generating this additional cardiovascular risk.

4 s with type 2 diabetes mellitus and elevated cardiovascular risk.

5 ative stress, both associated with increased cardiovascular risk.

6 metabolic abnormalities leading to increased cardiovascular risk.

7 Adults with high blood pressure and elevated cardiovascular risk.

8 ) emerges as systemic disease with increased cardiovascular risk.

9 effects of pravastatin (40 mg once daily) on cardiovascular risk.

10 ides 1 potential explanation for age-related cardiovascular risk.

11 ciated with pill burden than their degree of cardiovascular risk.

12 2 participants with type 2 diabetes and high cardiovascular risk.

13 th period of HD which may explain changes in cardiovascular risk.

14 ), that involved 15 067 participants at high cardiovascular risk.

15 aque burden with CVRFs and estimated 10-year cardiovascular risk.

16 n patients with moderate COPD and heightened cardiovascular risk.

17 ic interventions and ultimately help predict cardiovascular risk.

18 g atherogenic remnant cholesterol may reduce cardiovascular risk.

19 of 0.5 or greater is associated with future cardiovascular risk.

20 sults of clinical trials in patients at high cardiovascular risk.

21 type 2 diabetes in order to rule out excess cardiovascular risk.

22 Patients with type 2 diabetes have increased cardiovascular risk.

23 er disease but may confer protection against cardiovascular risk.

24 holesterol efflux capacity is predictive for cardiovascular risk.

25 ifestyle-based strategies designed to reduce cardiovascular risk.

26 pollutant concentrations are associated with cardiovascular risk.

27 process began with an assessment of overall cardiovascular risk.

28 al evidence links arterial calcification and cardiovascular risk.

29 rogate marker of endothelial dysfunction and cardiovascular risk.

30 , elevated C-reactive protein level predicts cardiovascular risk.

31 tribute new information to the prediction of cardiovascular risk.

32 rm therapies, such as statins, that mitigate cardiovascular risk.

33 shown that lowering LDL-C generally reduces cardiovascular risk.

34 efficacy of bococizumab in patients at high cardiovascular risk.

35 ar events (CVEs) in patients who are at high cardiovascular risk.

36 n to sensor-estimated activity or calculated cardiovascular risk.

37 to whether testosterone treatment increases cardiovascular risk.

38 procedural success and reduce postprocedural cardiovascular risk.

39 lammatory and other proteins associated with cardiovascular risks.

40 , but virtually nothing is known about their cardiovascular risks.

41 ACb=CAC5y=0 (10-year coronary and hard/total cardiovascular risk: 1.4%, 2.0%, and 2.8%), which was fo

42 recommendations address assessment of total cardiovascular risk (5 guidelines), dysglycemia (7 guide

43 uced cardiac baroreflex sensitivity heighten cardiovascular risk, althogh whether such autonomic dysf

44 emporal trends in 10-year predicted absolute cardiovascular risk and cardiovascular risk factors amon

45 rdiac troponin T (hs-cTnT) is a biomarker of cardiovascular risk and could be approved in the United

46 cohorts were young (mean age=47.9), with low cardiovascular risk and moderate skin disease.

47 measurements have major potential to assess cardiovascular risk and monitor the impact of therapeuti

48 h other conditions associated with increased cardiovascular risk and more rigorous cardiovascular dis

49 Despite effective therapies to lower the cardiovascular risk and prevent progression to critical

50 tment with global RAS antagonists attenuates cardiovascular risk and slows the progression of protein

51 ts is associated with approximately the same cardiovascular risk as NSAIDs with less cyclooxygenase-2

52 not support the clinical use of NAG ratio in cardiovascular risk assessment in a low-risk group.

53 of the BiomarCaRE consortium (Biomarker for Cardiovascular Risk Assessment in Europe), we examined A

54 Cardiovascular risk assessment is a fundamental componen

55 dio-oncology clinic for pre-cancer treatment cardiovascular risk assessment.

56 cer uptake and plaque phenotype or predicted cardiovascular risk (ASSIGN score [Assessing Cardiovascu

57 isk factors, may contribute to the increased cardiovascular risk associated with CKD.

58 consistent in subgroups defined according to cardiovascular risk at baseline, lipid level, C-reactive

59 ide unique information for the assessment of cardiovascular risk attributable to BP burden in renal t

60 n some adults aged 60 years or older at high cardiovascular risk, based on individualized assessment,

61 ng overweight or obese patients at increased cardiovascular risk, based on the interim analyses perfo

62 upus and rheumatoid arthritis associate with cardiovascular risk, but it is unknown whether particula

63 ects of hepatitis C virus (HCV) infection on cardiovascular risk, but these have produced ambiguous r

64 ticipants with hypertension and an increased cardiovascular risk, but without diabetes, the rates of

65 The cohort had a low cardiovascular risk by Framingham risk score and mild-to

66 "2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk" by allowing clinicians to estimate

67 ltration rate, lipid levels, and measures of cardiovascular risk (carotid intima-media thickness and

68 ich a greater than 1% prevalence of elevated cardiovascular risk could be ruled out (that is, the upp

69 patients have persistently elevated residual cardiovascular risk due to inadequate lowering of LDL-C

70 The LPA locus link with cardiovascular risk exemplifies how detailed metabolic p

71 the overall and marginal impact of favorable cardiovascular risk factor (CRF) profile on healthcare e

72 Timing and trajectories of cardiovascular risk factor (CVRF) development in relatio

73 Hypertension is considered a powerful cardiovascular risk factor and is present in up to two-t

74 Cardiovascular risk factor distribution and lipid profil

75 is available whether air pollution distorts cardiovascular risk factor distribution.

76 d related traits suggesting that traditional cardiovascular risk factor management may only have limi

77 ing the efficacy of this strategy for global cardiovascular risk factor modification are lacking.

78 At least 1 cardiovascular risk factor was present in 1,225 (83%) pa

79 y lipoprotein-like lipoprotein and important cardiovascular risk factor whose cognate receptor and in

80 T2D), and diabetic kidney disease is a major cardiovascular risk factor.

81 s >/=55 years of age with at least one other cardiovascular risk factor.

82 ) is associated with lower renal function, a cardiovascular risk factor.

83 Before NHL diagnosis, 39% had >/= 1 cardiovascular risk factor; 92% of survivors were treate

84 rior angiogram, 72 LT recipients matched for cardiovascular risk factors (control group I), and 119 c

85 erosclerosis improves risk prediction beyond cardiovascular risk factors (CVRFs) and risk scores, but

86 Absence of cardiovascular risk factors (CVRFs) is traditionally con

87 The higher prevalence of traditional cardiovascular risk factors (eg, hypertension, diabetes

88 95% CI, 1.01-2.15), and 3 or more component cardiovascular risk factors (HR, 1.58; 95% CI, 1.13-2.33

89 among adults without obesity who do not have cardiovascular risk factors (hypertension, dyslipidemia,

90 and 35.5+/-10.1 mL/m(2) in subjects free of cardiovascular risk factors (n=283).

91 tedly high overall prevalence of established cardiovascular risk factors (obesity, diabetes mellitus,

92 ) participating in an international study of cardiovascular risk factors (the Multinational mONItorin

93 pite wide heterogeneity in the prevalence of cardiovascular risk factors across different regions, CV

94 Demographic characteristics and cardiovascular risk factors among those with type 1 and

95 r predicted absolute cardiovascular risk and cardiovascular risk factors among US adults in different

96 azard ratios (HRs) for 12 CVDs, adjusted for cardiovascular risk factors and acute conditions affecti

97 haracterisation and define the role of other cardiovascular risk factors and advanced subclinical cor

98 age/sex-matched controls were evaluated for cardiovascular risk factors and carotid plaque on ultras

99 We assessed cardiovascular risk factors and determined clinical stro

100 lineated the association between traditional cardiovascular risk factors and development of aortic st

101 h as trastuzumab is predicted by preexisting cardiovascular risk factors and disease, posing the ques

102 ological approaches for the ascertainment of cardiovascular risk factors and events.

103 examined the association between traditional cardiovascular risk factors and incident severe AS in a

104 e associations between childhood/adolescence cardiovascular risk factors and midlife cognitive perfor

105 roved to treat obesity, but their effects on cardiovascular risk factors and outcomes are not well de

106 in FD is associated with a higher burden of cardiovascular risk factors and preclinical indices of C

107 ically evaluated the association of standard cardiovascular risk factors and SCA, and sports as a tri

108 Besides its associations with traditional cardiovascular risk factors and stroke, associations bet

109 We evaluated the impact of living in FD on cardiovascular risk factors and subclinical cardiovascul

110 ctional associations between urinary NAG and cardiovascular risk factors and the longitudinal associa

111 Those without traditional cardiovascular risk factors are disproportionately prone

112 gh reduced cardiac output and high burden of cardiovascular risk factors are the prevailing explanati

113 of public health approaches that screen for cardiovascular risk factors at earlier ages.

114 ociation exists between decreasing number of cardiovascular risk factors at target and major adverse

115 independently associated with the number of cardiovascular risk factors controlled.

116 Cardiovascular risk factors for IPH volume change were i

117 Cumulative burden of cardiovascular risk factors from childhood/adolescence a

118 Survivors with cardiovascular risk factors had an increased risk of HF

119 The cumulative burden and importance of cardiovascular risk factors have changed over the past d

120 disease in which both traditional and novel cardiovascular risk factors have effects on outcomes.

121 scriptions of geographic variations in major cardiovascular risk factors have relied on data aggregat

122 stic information over and beyond traditional cardiovascular risk factors in a large, population-based

123 Comorbidities and cardiovascular risk factors in adolescent surgical patie

124 tal cycles for three days) adversely affects cardiovascular risk factors in healthy adults.

125 alignment using forced desynchrony increases cardiovascular risk factors in humans.

126 Cardiovascular risk factors in midlife (specifically ele

127 ozin improved various glycaemic measures and cardiovascular risk factors in patients with type 2 diab

128 aper, we review the specific role of several cardiovascular risk factors in promoting oxidative stres

129 Although the presence of standard cardiovascular risk factors in the young can link to fut

130 ed cardiovascular events, and the control of cardiovascular risk factors in this context is essential

131 hts the importance of lifelong monitoring of cardiovascular risk factors in women with a history of p

132 ith calcified plaque burden (P < 0.0001) and cardiovascular risk factors including age (P < 0.0001),

133 loid (cerebral amyloid angiopathy (CAA), and cardiovascular risk factors increase dementia risk.

134 It is less clear whether cardiovascular risk factors influence PD phenotype, and

135 er time in most countries, the prevalence of cardiovascular risk factors may also be decreasing among

136 All established cardiovascular risk factors such as hypercholesterolemia

137 Cardiovascular risk factors tend to aggregate.

138 o understand the contribution of preexisting cardiovascular risk factors to HF risk among NHL survivo

139 rdiovascular disease in adults without known cardiovascular risk factors to inform the US Preventive

140 The relationship of demographics and cardiovascular risk factors to LA size is largely unknow

141 ert favourable results in a variety of other cardiovascular risk factors too, such as increased blood

142 ors reduce glycaemia and weight, and improve cardiovascular risk factors via different mechanisms.

143 Standard cardiovascular risk factors were found in over half of p

144 duration and at least three of ten specific cardiovascular risk factors were randomly assigned (via

145 (n = 135, 66 males, age 23-83 years) without cardiovascular risk factors were recruited.

146 Classical cardiovascular risk factors were self-reported.

147 riable analyses adjusted for albuminuria and cardiovascular risk factors, a baseline NAG ratio in the

148 model, adjusting for age, sex, demographics, cardiovascular risk factors, and apolipoprotein E genoty

149 bnormal blood glucose levels and diabetes as cardiovascular risk factors, and application of the guid

150 Demographic covariates, cardiovascular risk factors, and cardiac MR measurements

151 ears with hypertension, at least three other cardiovascular risk factors, and fasting total cholester

152 ression analyses adjusting for demographics, cardiovascular risk factors, and left ventricular (LV) m

153 ificant predictor after adjustment for other cardiovascular risk factors, angiography result, or stra

154 In multivariable models adjusted for cardiovascular risk factors, both higher carotid-femoral

155 ng, gathering, fishing, and farming with few cardiovascular risk factors, but high infectious inflamm

156 over, we compared patient age, prevalence of cardiovascular risk factors, clinical stroke severity, i

157 erfiltration, insulin sensitivity, and other cardiovascular risk factors, effects that might translat

158 We adjusted for demographics, cardiovascular risk factors, eGFR, and urine albumin-to-

159 populations, poor, and have higher rates of cardiovascular risk factors, especially smoking and hype

160 o be stronger in the presence of traditional cardiovascular risk factors, especially the synergistic

161 stment for social determinants of health and cardiovascular risk factors, hazard ratios in ARIC and R

162 Traditional cardiovascular risk factors, HIV viral load, CD4 lymphoc

163 ents regarding drug safety, effects on major cardiovascular risk factors, impact on cardiovascular ou

164 uninfected controls similar in age, sex, and cardiovascular risk factors, including diabetes mellitus

165 h reduced mortality was independent of other cardiovascular risk factors, including eGFR, and stronge

166 ortality than maximal MBF beyond traditional cardiovascular risk factors, left ventricular ejection f

167 Additional adjustment included cardiovascular risk factors, notably hypertension, serum

168 uded adjustment for demographics, ethnicity, cardiovascular risk factors, serological studies, socioe

169 x, ethnicity, socioeconomic characteristics, cardiovascular risk factors, site, and CT scanner techno

170 .02) or for age, sex, adulthood conventional cardiovascular risk factors, socioeconomic status, socia

171 ian persons and associated with conventional cardiovascular risk factors, stroke, and chronic kidney

172 eparate the contributions of obesity-related cardiovascular risk factors, such as diabetes and hypert

173 After adjustment for cardiovascular risk factors, the OR for CVD per 1-standa

174 ng CAC score to models including traditional cardiovascular risk factors, with only age being removed

175 group intervention had beneficial effects on cardiovascular risk factors, with significant improvemen

176 as compared with calcified plaque burden and cardiovascular risk factors.

177 severity, infarct volume, brain volume, and cardiovascular risk factors.

178 djusted for potential confounders, including cardiovascular risk factors.

179 diabetic patients had a higher prevalence of cardiovascular risk factors.

180 ultivariable models adjusted for established cardiovascular risk factors.

181 and low risk of cardiac events, according to cardiovascular risk factors.

182 coronary heart disease after adjustment for cardiovascular risk factors.

183 iovascular events independent of traditional cardiovascular risk factors.

184 factors, cardiac structure and function, and cardiovascular risk factors.

185 and low socioeconomic status as synergistic cardiovascular risk factors.

186 n dose to the heart, chemotherapy, and other cardiovascular risk factors.

187 own that obesity is associated with multiple cardiovascular risk factors.

188 yses were adjusted for mean LDL-C levels and cardiovascular risk factors.

189 ustment for age or additional adjustment for cardiovascular risk factors.

190 c differences in socioeconomic status and/or cardiovascular risk factors.

191 ulations with high prevalence of traditional cardiovascular risk factors.

192 rds models were adjusted for demographic and cardiovascular risk factors.

193 the risk was attenuated after adjusting for cardiovascular risk factors.

194 56-80] years) and had a higher prevalence of cardiovascular risk factors.

195 onceptually as an accelerator of traditional cardiovascular risk factors.

196 ly adjusted for each other, and conventional cardiovascular risk factors.

197 Midlife and concurrent cardiovascular risk factors.

198 lated to AF independent of demographical and cardiovascular risk factors.

199 onfounding influence of variable exposure to cardiovascular risk factors.

200 rosclerosis and is linked to the presence of cardiovascular risk factors.

201 n the top-20 lists as opposed to traditional cardiovascular risk factors.

202 t the whole disease spectrum, independent of cardiovascular risk factors.

203 for patients with serious mental illness and cardiovascular risk factors.

204 ot benefited equally from efforts to control cardiovascular risk factors.

205 HF compared with those with none (for 1 v 0 cardiovascular risk factors: HR, 1.63; 95% CI, 1.07 to 2

206 R, 1.63; 95% CI, 1.07 to 2.47; for >/= 2 v 0 cardiovascular risk factors: HR, 2.86; 95% CI, 1.56 to 5

207 Previous studies have been unclear about the cardiovascular risks for metabolically healthy obese ind

208 10 overweight or obese patients at increased cardiovascular risk from June 13, 2012, to January 21, 2

209 ree of diabetes at baseline but were at high cardiovascular risk from the PREvencion con DIeta MEDite

210 ults aged 40 to 59 years with a mean 30-year cardiovascular risk greater than 30%, and 28% would have

211 of N-acetyl-beta-D-glucosaminidase (NAG) and cardiovascular risk has been assessed mostly in cross-se

212 with type 2 diabetes mellitus and increased cardiovascular risk have demonstrated a cardiovascular b

213 C) is a well established metabolic marker of cardiovascular risk, however, its role in pulmonary arte

214 ervous system (SNS) that could contribute to cardiovascular risk; however, sympathetic function has n

215 c measure, which might be used for assessing cardiovascular risk in a population-based cohort.

216 the association between low birth weight and cardiovascular risk in adulthood.

217 Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults, low-density lipoprotein c

218 dy, a community-based observational study of cardiovascular risk in black adults, we measured serum e

219 between prenatal air pollution on markers of cardiovascular risk in childhood.

220 enous antioxidant and has been identified as cardiovascular risk in cohort studies, while the relatio

221 Posttrial follow-up of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Lipid Study bet

222 ts from the ACCORD-BP (The Action to Control Cardiovascular Risk in Diabetes blood pressure) trial.

223 ons, we used data from the Action to Control Cardiovascular Risk in Diabetes study (ACCORD, n=9635; 2

224 orted in the ACCORD trial [Action to Control Cardiovascular Risk in Diabetes]) is unclear.

225 ential mechanisms responsible for the higher cardiovascular risk in DM patients.

226 Increased cardiovascular risk in mothers having male offspring sug

227 y influences adiposity change and subsequent cardiovascular risk in multiethnic populations.

228 score) for CVD complications after OLT, the Cardiovascular Risk in Orthotopic Liver Transplantation

229 bition with evolocumab significantly reduced cardiovascular risk in patients with and without diabete

230 d arterial stiffness contribute to increased cardiovascular risk in patients with CKD who exhibit chr

231 ysfunction, blocking inflammation may reduce cardiovascular risk in patients with CKD.

232 Precise stratification of cardiovascular risk in patients with coronary heart dise

233 e describe may help to explain the increased cardiovascular risk in RA, and raises the possibility th

234 alcohol drinking was associated with higher cardiovascular risk in the following day ( approximately

235 concentrations in plasma are associated with cardiovascular risk in the general population.

236 Dogs may be beneficial in reducing cardiovascular risk in their owners by providing social

237 has substantially affected the management of cardiovascular risk in these patients.

238 Excess cardiovascular risk in women was independently associate

239 DS AND A total of 2262 participants from the Cardiovascular Risk in YFS (Young Finns Study) were foll

240 r hundred and twenty-two participants of the Cardiovascular Risk in Young Finns Study who had partici

241 nts of Adult Health Study), and Finland (The Cardiovascular Risk in Young Finns Study) and followed i

242 011 within the longitudinal population-based Cardiovascular Risk in Young Finns Study.

243 KEY POINTS: In hypertensive adults (HTN), cardiovascular risk increases disproportionately during

244 urden was directly associated with estimated cardiovascular risk independently of the number of plaqu

245 idence for a link between sleep duration and cardiovascular risk is accumulating in youths, but no st

246 d cholesterol concentrations), some residual cardiovascular risk is not reduced by implementation of

247 h restriction (IUGR) and leads to heightened cardiovascular risks later in life.

248 t suggest that it might have a wider role in cardiovascular risk management.

249 lesterol efflux capacity is not a prognostic cardiovascular risk marker in this cohort of patients wi

250 asis, with dysregulation of inflammatory and cardiovascular risk markers, strongly supporting its sys

251 ncy, emergence of microvascular changes, and cardiovascular risk may identify opportunities for futur

252 at the femoral level, and reflects estimated cardiovascular risk more closely than plaque detection a

253 ients with ESRD suffer an exceptionally high cardiovascular risk not fully explained by traditional r

254 We hypothesized that the increased cardiovascular risk observed in psoriasis would be parti

255 percentage of adults with predicted absolute cardiovascular risk of 20% or more, mean systolic blood

256 part of the pathophysiology of the increased cardiovascular risk of earlier menopause.

257 cussions, and includes available evidence on cardiovascular risk, pre-participation evaluation, and t

258 chine learning may be useful to characterize cardiovascular risk, predict outcomes, and identify biom

259 erum uromodulin concentration to established cardiovascular risk prediction scores improved risk pred

260 this pattern presented a significantly worse cardiovascular risk profile and, after adjustment for ri

261 of patients with type 2 diabetes and a broad cardiovascular risk profile, SGLT2 inhibitor use was ass

262 In patients with type 2 diabetes and a high cardiovascular risk profile, the sodium-glucose co-trans

263 lowering drugs, in a population with a broad cardiovascular risk profile.

264 The two groups of patients had comparable cardiovascular risk profiles and blood pressure througho

265 To better define serum inflammatory and cardiovascular risk proteins, we used an OLINK high-thro

266 orodeoxyglucose did correlate with predicted cardiovascular risk (r=0.53, P=0.019), but not with plaq

267 que burden [r=0.51, P=0.004]), and predicted cardiovascular risk [r=0.65, P=0.002]).

268 lerance, and describe approaches to optimize cardiovascular risk reduction among individuals reportin

269 d on-treatment analysis showed a significant cardiovascular risk reduction in those who used CPAP for

270 The Cardiovascular Risk Reduction Model was developed by Mil

271 gram designed to evaluate the Million Hearts Cardiovascular Risk Reduction Model.

272 Clinical strategies that optimize cardiovascular risk reduction through LDL-C lowering nee

273 sity to type 2 diabetes mellitus with excess cardiovascular risk, represents a major public health bu

274 indicate lower, average, or higher relative cardiovascular risk, respectively.

275 for general populations: Framingham general cardiovascular Risk Score (FRS), American College of Car

276 ediated by white matter hyperintensities and cardiovascular risk score each explaining 10.4% and 21.6

277 We present two cardiovascular risk scores, with and without laboratory-

278 ovascular outcomes in comparison to standard cardiovascular risk scores.

279 The optimal cardiovascular risk stratification approach in this evol

280 al of plasma lipid species as biomarkers for cardiovascular risk stratification in diabetes mellitus.

281 and function may provide novel insights for cardiovascular risk that extend beyond traditional plasm

282 on was associated with an immediately higher cardiovascular risk that was attenuated after 24 hours,

283 c inflammation is thought to drive increased cardiovascular risk through accelerated atherosclerosis.

284 using single thresholds to identify elevated cardiovascular risk throughout the childhood years and t

285 igned patients with type 2 diabetes and high cardiovascular risk to receive liraglutide or placebo.

286 Trial), patients with hypertension and high cardiovascular risk treated with intensive blood pressur

287 n patients with moderate COPD and heightened cardiovascular risk, treatment with fluticasone furoate

288 betes mellitus, obesity, and atherosclerotic cardiovascular risk) underlies the relatively earlier ag

289 cardiovascular risk (ASSIGN score [Assessing Cardiovascular Risk Using SIGN Guidelines to Assign Prev

290 We assessed predicted absolute cardiovascular risk using the pooled cohort equation.

291 Cardiovascular risk was quantified using the QRISK2 calc

292 ons on systemic inflammation associated with cardiovascular risks, we studied blood proteins related

293 5 patients with moderate COPD and heightened cardiovascular risk were included in the study.

294 1 to 399 to CAC5y>/=400, coronary and total cardiovascular risk were nearly 2-fold in comparison wit

295 r rheumatoid arthritis and were at increased cardiovascular risk were randomly assigned to receive ce

296 DL cholesterol levels among patients at high cardiovascular risk who had elevated LDL cholesterol lev

297 bo in patients with type 2 diabetes and high cardiovascular risk who were receiving usual care, we fo

298 n effects of alcohol on lipid metabolism and cardiovascular risk, with light alcohol use generally be

299 with significant, though more modest, excess cardiovascular risks, with corresponding HRs of 1.66 (95

300 iovascular disease on the basis of predicted cardiovascular risk without directly considering the exp